Hellenic Journal of Cardiology最新文献

{"title":"Comparison of continuous flow centrifugal left ventricular assist devices as a bridge to transplant strategy in a low organ donation environment: Single center experience.","authors":"Michael Bonios, Dimitris Miliopoulos, Angeliki Gkouziouta, Nektarios Kogerakis, Sokratis Fragkoulis, Iakovos Armenis, Dimitrios Zarkalis, Konstantinos Ieromonachos, Antigoni Koliopoulou, Evangelos Leontiadis, Panagiota Georgiadou, Vasiliki Vartela, Dimitrios Tsiapras, Petros Sfirakis, Christos Kapelios, Stavros Dimopoulos, Loukas Kaklamanis, Dimitrios Ntegiannis, Theofani Antoniou, Themistokles Chamogeorgakis, Stamatis Adamopoulos","doi":"10.1016/j.hjc.2024.10.004","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.004","url":null,"abstract":"<p><strong>Background: </strong>In advanced heart failure patients, heart transplantation is currently the most effective treatment. However, in a low-organ environment, it is usually necessary to proceed in long-term mechanical circulatory support through left ventricular assist device (LVAD) implantation as bridge-to-transplantation METHODS: The study included all patients with advanced heart failure who underwent continuous flow LVAD implantation as a bridge to transplant strategy in our centre (n = 68). Following LVAD implantation and for the period that patients were on LVAD support, pump thrombosis, strokes, gastrointestinal bleeding and right heart failure occurrence rates were recorded. Outcomes were compared between patients implanted with HeartMate 3 (HM3) and HeartWare (hVAD) LVADs as well as between patients who did reach heart transplantation (HTx group) and those who did not (noHTx group).</p><p><strong>Results: </strong>35 out of 68 patients underwent heart transplantation at a mean time of 691 ± 457 days. 41 patients received a HeartWare hVAD and 27 a HeartMate 3 (HM3) device. HM3 patients had significantly better survival (p = 0.010) and lower complication rates (p = 0.025). Additionally, the noHTx group had significantly higher complication rates compared to the HTx group (p = 0.00041). The five-year estimated Kaplan-Meier survival rates following heart transplantation was 77%.</p><p><strong>Conclusions: </strong>Patients with advanced heart failure gain substantial benefit from left ventricular assist devices awaiting heart transplantation. In a low organ donation environment, the need for reliable left ventricular assist devices can further improve the outcomes through the reduction of complications provided by current devices.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of three-month treatment with pitavastatin on arterial stiffness in patients with hypercholesterolemia: a prospective observational study.","authors":"Hack-Lyoung Kim, Soonil Kwon, Hyun Sung Joh, Woo-Hyun Lim, Jae-Bin Seo, Sang-Hyun Kim, Joo-Hee Zo, Myung-A Kim","doi":"10.1016/j.hjc.2024.10.005","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.005","url":null,"abstract":"<p><strong>Background: </strong>Although several studies have highlighted the benefits of statins in improving arterial stiffness, there is limited research on whether pitavastatin, a more recently developed statin, has similar effects. This study aimed to investigate the impact of pitavastatin on arterial stiffness in patients with hypercholesterolemia.</p><p><strong>Methods: </strong>This prospective study enrolled 115 patients with hypercholesterolemia (mean age 59 years; 22% female) who had not previously been treated with statins. Participants underwent lifestyle interventions followed by administration of pitavastatin (2 or 4 mg daily) if target low-density lipoprotein (LDL) cholesterol levels were not achieved. The primary outcome measured was the change in brachial-ankle pulse wave velocity (baPWV) from baseline after three months of treatment.</p><p><strong>Results: </strong>Pitavastatin treatment significantly reduced LDL cholesterol by 41.1% (from 158 ± 28 to 93.0 ± 29.6 mg/dL; P < 0.001). Additionally, systolic blood pressure (SBP) decreased significantly from 130 ± 14 mmHg to 126 ± 14 mmHg (P < 0.001), representing a 2.9% reduction, and baPWV decreased significantly from 1,522 ± 325 to 1,407 ± 289 cm/s (P < 0.001), a 7.6% reduction. There was a significant correlation between changes in SBP and changes in baPWV (r = 0.565; P < 0.001). Even after adjusting for changes in SBP, the reduction in baPWV induced by pitavastatin remained statistically significant (P < 0.001).</p><p><strong>Conclusions: </strong>A three-month treatment with pitavastatin effectively reduced arterial stiffness in patients with hypercholesterolemia, alongside significant improvements in lipid profiles and blood pressure reductions. These findings support the use of pitavastatin for managing key cardiovascular risk factors.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodality imaging for the diagnosis of giant cavernous hemangioma of the right ventricle.","authors":"Leizhi Ku, Youping Cheng, Yuhang Wang, Zheng Liu, Xiaojing Ma","doi":"10.1016/j.hjc.2024.10.003","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.003","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the predictive ability of GRACE 2.0 and GRACE 3.0 scores in a Greek cohort of patients hospitalized with acute coronary syndrome.","authors":"Christos Kofos, Andreas S Papazoglou, Stavroula Rousopoulou, Paraskevi Douki, Andreas Takas, Athanasios Samaras, Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, Barbara Fyntanidou, Nikolaos Fragakis, George Kassimis","doi":"10.1016/j.hjc.2024.10.002","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.002","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New guidelines of EACTS/STS on aortic disease: A useful tool for the management of \"aortic organ\" disease.","authors":"Nikolaos Schizas, Panagiotis Dedeilias","doi":"10.1016/j.hjc.2024.10.001","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.001","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Cardiovascular Drugs in Hyperglycemia and Diabetes: A review of 'Unspoken Side' Effect.","authors":"Wynne Widiarti, Pandit Bagus Tri Saputra, Cornelia Ghea Savitri, Johanes Nugroho Eko Putranto, Firas Farisi Alkaff","doi":"10.1016/j.hjc.2024.09.007","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.09.007","url":null,"abstract":"<p><strong>Aims: </strong>The increasing prevalence of cardiovascular diseases has led to widespread use of cardiovascular drugs that can adversely impact glucose metabolism. This review focuses on the latest evidence on the potential of cardiovascular drugs to induce adverse glycemic effects but also the underlying mechanisms, prevention, and management strategies.</p><p><strong>Materials and methods: </strong>A comprehensive literature search was conducted across scientific databases until May 25th, 2024.</p><p><strong>Results: </strong>Certain cardiovascular drugs can induce hyperglycemia through multiple mechanisms including altered the secretion and sensitivity of insulin through direct cytotoxic effects towards pancreatic beta cells, and increased glucose secretion. Notably, diuretics, beta-blockers, calcium channel blockers, and statins have been associated with significant glycemic disturbances. The risk of hyperglycemia varies based on individual factors, drug dosages, and concurrent medications. These drug-induced hyperglycemic effects may sometimes reverse upon discontinuation of related medication. Effective management should include lifestyle modifications, the use of glucose-lowering medications, and opting for lower-risk cardiovascular drugs. Monitoring for hyperglycemia involves educating affected individuals and conducting regular blood glucose tests. Identifying at-risk individuals and implementing preventive measures are crucial for improving both cardiovascular and metabolic outcomes.</p><p><strong>Conclusions: </strong>Certain cardiovascular drugs significantly contribute to hyperglycemia and diabetes mellitus through various mechanisms. Effective management includes identifying at-risk individuals, choosing lower-risk medications, and implementing monitoring and preventive strategies. Further research is needed to fully understand these mechanisms and develop targeted interventions to prevent and manage cardiovascular drug-induced hyperglycemia, thereby improving clinical outcomes.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECMO versus IABP for STEMI Patients Complicated by Cardiogenic Shock undergoing Primary PCI: A Chinese National Study and Propensity-matched Analysis.","authors":"Hongbo Yang, Lingfeng Luo, Yanan Song, Jiatian Cao, Jing Chen, Feng Zhang, Yiwen Tan, Yan Zheng, Zhonghan Sun, Juying Qian, Zheyong Huang, Junbo Ge","doi":"10.1016/j.hjc.2024.09.008","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.09.008","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the association between the utilization of extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) and in-hospital mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock undergoing primary percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>Data encompassing 9635 cases of STEMI complicated by cardiogenic shock and treated with primary PCI using ECMO/IABP support were retrieved from the Chinese Cardiovascular Association database (2019-2021). We conducted an analysis to assess in-hospital survival disparities among percutaneous mechanical circulatory device recipients and explore the potential advantages of ECMO through multivariable logistic regression analysis within a propensity score-matched (1:2) cohort population.</p><p><strong>Results: </strong>ECMO was administered to 2028 patients, while IABP was utilized in 7607 patients. Patients supported by ECMO showed a lower in-hospital mortality compared with those supported by IABP (7.2% vs. 15.1%, p<0.001). Within the propensity-matched (case : control=1:2) cohort, we noted a 34% reduced risk of in-hospital mortality among patients supported by ECMO compared to those supported by IABP (7.7% vs. 11.7%; odds ratio = 0.66; 95% CI, 0.53-0.80; p< 0.001) independent of age, sex, systolic blood pressure, obesity, smoke, hypertension, diabetes, dyslipidaemia, family history of coronary artery disease, coronary artery disease, stroke, atrial filiation, peripheral artery disease, chronic kidney disease, vascular lesion sites, 3A-grade hospital, and regional distributions in China.</p><p><strong>Conclusions: </strong>Among patients undergoing primary PCI for STEMI complicated by cardiogenic shock, ECMO was associated with better in-hospital survival than IABP.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central versus peripheral VA ECMO for cardiogenic shock: an 8-year experience of a tertiary cardiac surgery center in Greece.","authors":"Michael Antonopoulos, Antigone Koliopoulou, Dimitrios Elaiopoulos, Kyriaki Kolovou, Dimitra Doubou, Anna Smyrli, Prodromos Zavaropoulos, Nektarios Kogerakis, Sokratis Fragoulis, Konstantinos Perreas, Georgios Stavridis, Stamatis Adamopoulos, Themistocles Chamogeorgakis, Stavros Dimopoulos","doi":"10.1016/j.hjc.2024.09.006","DOIUrl":"10.1016/j.hjc.2024.09.006","url":null,"abstract":"<p><strong>Background: </strong>VA ECMO has emerged as an effective rescue therapy in patients with cardiogenic shock refractory to standard treatment protocols and its use is rising worldwide in the last decade. Although experience and availability are growing, outcomes remain poor. There is need for evidence to ameliorate clinical practice and improve outcomes.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of all patients who were supported with VA ECMO for cardiogenic shock at our institution between January 2015 and January 2023. The study purpose was to compare outcomes between patients who were supported with central versus peripheral configuration.</p><p><strong>Results: </strong>ECMO was applied in 108 patients of whom central configuration in 48 (44%) and peripheral in 60 (56%). Patients supported with central VA ECMO were more likely to be supported for post cardiotomy shock [OR 4.6 (CI 95% 2.03 - 10.41)], while patients in the peripheral group for chronic heart failure decompensation [OR 9.4 (CI 95% 1.16 - 76.3]. Central VA ECMO had worse survival during ECMO support (29.2% vs 51.7%, p=0.018) and at discharge (8% vs 37%, p=0.001). These patients were at high risk of complications, such as acute kidney injury (AKI), [OR 2.37 (CI 95% 1.06 - 5.3), p = 0.034] and major bleeding [OR 3.08 (CI 95% 1.36 - 6.94), p<0.001].</p><p><strong>Conclusions: </strong>Patients on central VA ECMO were supported mainly for post cardiotomy shock, presented with more complications such as major bleeding and AKI and had worse survival to hospital discharge, compared with patients on peripheral VA ECMO. Patient selection, timing of implementation, cannulation strategy and configuration remain main determinants of clinical outcome.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Polymer-Free Biolimus-eluting Stents versus Durable Polymer Novolimus-eluting Stents in a Real-World Clinical Practice (FREEDOM-DES Trial).","authors":"Soohyung Park, Seung-Woon Rha, Byoung Geol Choi, Sang Ho Park, Jae-Bin Seo, Ju Yeol Baek, Jae Woong Choi, Yong Hoon Kim, Ji-Hun Ahn, Gi Chang Kim, Weon Kim, Soo-Han Kim, Markz Rmp Sinurat, Se Yeon Choi, Jin Ah Cha, Soo Jin Hyun, Cheol Ung Choi, Chang Gyu Park","doi":"10.1016/j.hjc.2024.09.005","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.09.005","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is endocarditis always the answer?","authors":"Oikonomidis Dimitrios, Pappas Alexandros, Tatsis Evangelos, Tasoulis Athanasios, Papadopoulos Constantinos","doi":"10.1016/j.hjc.2024.09.004","DOIUrl":"10.1016/j.hjc.2024.09.004","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}